Dr. Usman is currently President & CEO and a member of the Board of Directors at Catalyst Biosciences (NASDAQ:CBIO). Dr. Usman joined Catalyst from Morgenthaler Ventures, where he is a Venture Partner. Prior to joining Morgenthaler in 2005, he was Senior Vice President and Chief Operating Officer at Sirna Therapeutics Inc. (Nasdaq:RNAI – acquired by Merck NYSE:MRK) from 2004 to 2005 and held various R&D positions at both Sirna and Ribozyme Pharmaceuticals (Nasdaq:RZYM), including VP of R&D and Chief Scientific Officer, from 1992 to 2004. During his industrial career, Dr. Usman has entered several drugs into clinical development, completed multiple licensing deals with pharmaceutical and biotechnology companies and raised capital in both private and public financings. Prior to moving into the biotechnology industry in 1992, Dr. Usman was an NIH Fogarty and NSERC Postdoctoral Fellow and Scientist in the Departments of Biology and Chemistry at the Massachusetts Institute of Technology from 1987 to 1992. He has authored more than 70 scientific articles and 130 patents and applications. Dr. Usman serves on the Boards of Mosaic Biosciences and Principia Biopharma, is a past director of Osprey Pharmaceuticals, Archemix Corporation and atugen AG (now Silence Therapeutics, LSE/AIM:SLN) and served on the SABs of RXi Pharmaceuticals and Noxxon Pharma AG. He received his B.Sc. (Honours) and Ph.D. in Organic Chemistry from McGill University. In his doctoral dissertation, he developed a method for the solid-phase synthesis of RNA that is widely used in science and in a marketed RNA product (Macugen™).